Live Analyst Rating Changes 46591 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Kemp Dolliver
BROO

Kemp Dolliver

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜†
#763
on 13Foresight Β· ranked by our own returns
26%
Success Rate
-23.8%
Average Return
6 of 23 calls profitable Β· -41.7% vs benchmark
S&P 500 (SPY)
πŸ”’ 3-year track record is Pro. Showing 1-year β€” upgrade.
πŸ“ˆ Across the calls we could measure, roughly 26% of Kemp Dolliver's ratings turned a profit when each position was held for 1 year β€” averaging -23.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

5 Buy 4 Hold 0 Sell
Kemp's Stock Coverage 28 ratings Β· 2026-10-25
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
LNTH
Lantheus
Jul 28, 2026 HOLD Strong Buy
-19.2% avg upside
21 analysts
$105.00
5.31% Upside
-2.6% Β·
LSTA
Lisata Therapeutics
Jul 27, 2026 HOLD Buy
+1200.3% avg upside
11 analysts
β€” -30.6% Β·
TSE:PINK
Perimeter Medical Imaging AI
Jul 13, 2026 BUY Strong Buy
+1375.4% avg upside
5 analysts
$1.54
805.83% Upside
Β· Β·
CLRB
Cellectar Biosciences
Jul 12, 2026 BUY Strong Buy
+5938.2% avg upside
8 analysts
$15.00
1129.50% Upside
-51.3% Β·
ICCM
Icecure Medical
Jun 17, 2026 BUY Strong Buy
+3690.1% avg upside
5 analysts
$73.50
7177.26% Upside
-83.6% Β·
RNTX
Rein Therapeutics
Jan 21, 2026 HOLD Buy
+1446.1% avg upside
6 analysts
β€” -51.9% Β·
VRCA
Verrica Pharmaceuticals
Dec 17, 2025 BUY Strong Buy
+385.1% avg upside
9 analysts
$17.00
381.62% Upside
-52.4% Β·
MNPR
Monopar Therapeutics Inc
Sep 25, 2025 BUY Strong Buy
+50.1% avg upside
18 analysts
$93.00
31.69% Upside
+10.1% Β·
IBIO
Ibio
Sep 05, 2025 BUY Strong Buy
+722.3% avg upside
13 analysts
$1.60
122.90% Upside
+56.0% Β·
BIOX
Bioceres Crop Solutions
Aug 22, 2025 HOLD Buy
+5334.8% avg upside
5 analysts
$26.00
10982.68% Upside
-85.0% Β·
DARE
DarΓ© Bioscience
Aug 18, 2025 BUY Strong Buy
+1976.2% avg upside
14 analysts
$11.00
1602.99% Upside
-63.6% Β·
RADX
Radiopharm Theranostics Limited Sponsored ADR
Jul 21, 2025 BUY Strong Buy
+1715.2% avg upside
6 analysts
$18.00
1682.24% Upside
-0.5% Β·
CADL
Candel Therapeutics
Jul 09, 2025 BUY Strong Buy
+143.4% avg upside
12 analysts
$25.00
211.38% Upside
+62.4% Β·
CATX
Perspective Therapeutics
Mar 10, 2025 BUY Strong Buy
+585.3% avg upside
24 analysts
$11.00
583.27% Upside
+110.6% Β·
HYPD
Hyperion DeFi
Nov 15, 2024 HOLD Buy
+206.3% avg upside
8 analysts
β€” -38.6% Β·
ADIL
Adial Pharmaceuticals
Feb 14, 2024 BUY Strong Buy
+1050.1% avg upside
7 analysts
$26.00
563.27% Upside
-35.1% Β·
OTLK
Outlook Therapeutics
Jan 24, 2024 BUY Buy
+1686.6% avg upside
11 analysts
$31.40
5946.69% Upside
-75.1% Β·
BGMS
Bio Green Med Solution
Dec 19, 2023 HOLD Strong Buy
+1280.2% avg upside
7 analysts
β€” Β· Β·
HEPA
Hepion Pharmaceuticals
Dec 07, 2023 HOLD Strong Buy
+35134.3% avg upside
9 analysts
β€” Β· Β·
GNLX
Genelux Corp.
Oct 31, 2023 BUY Strong Buy
+806.2% avg upside
8 analysts
$30.00
1399.97% Upside
-77.8% Β·
PROCF
Procaps Group
Sep 05, 2023 HOLD Hold
+17900.0% avg upside
1 analyst
$4.50
17900.02% Upside
Β· Β·
ECOR
Electrocore
Jul 11, 2023 BUY Buy
+509.7% avg upside
11 analysts
$23.00
226.20% Upside
+23.2% Β·
NOVN
Novan
Jun 14, 2023 HOLD Buy
7 analysts
β€” Β· Β·
NMTRQ
9 Meters Biopharma
May 25, 2023 HOLD Buy
+3234374900.0% avg upside
11 analysts
β€” Β· Β·
SCPX
Scorpius Holdings
May 01, 2023 HOLD Strong Buy
+18312400.0% avg upside
11 analysts
β€” Β· Β·
BIOCQ
Biocept
Jan 06, 2023 HOLD Buy
+8407499900.0% avg upside
7 analysts
β€” Β· Β·
EDSA
Edesa Biotech
Dec 16, 2022 BUY Strong Buy
+303.1% avg upside
6 analysts
$13.00
369.25% Upside
-21.9% Β·
SCYX
SCYNEXIS
Oct 20, 2022 BUY Strong Buy
+239.1% avg upside
10 analysts
$8.00
111.29% Upside
-25.6% Β·
πŸ”’ 23 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Kemp Dolliver β€” Frequently Asked Questions
How accurate are Kemp Dolliver's stock ratings?
Based on the calls 13Foresight could measure, about 26% of Kemp's ratings were profitable over a one-year hold, with an average return of -23.8% per rating, or -13.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kemp ranked on 13Foresight?
Kemp Dolliver is currently ranked #763 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kemp cover?
Kemp most recently has ratings on LNTH, LSTA, TSE:PINK, CLRB, ICCM, RNTX, VRCA, MNPR, IBIO, BIOX, DARE, RADX and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.